pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

3,932 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1824Endpoints1413Fierce Biotech735BioSpace724BioPharma Dive537raps241onclive165fda recalls
therapy area
allOncology12556Rare Disease3277Immunology2961Cardiology2832Hematology2224Pulmonology2200Vaccines
  • Sofinnova Partners raises €725M crossover fund to back later-stage European biotech firms
    Sofinnova Partners, a leading European life‑science venture firm, announced that it has closed a second crossover fund worth 725 million euros (about $815 million). The new vehicle, called Sofinnov…
    BioPharma Dive · 3h agoDealPositive↗ source
  • Emerging biotech hubs like India could help lower global drug costs by scaling development
    The article notes that every new therapy raises two core questions: can it be created and can society afford it. Historically biotech has focused on the first question. The author argues that as s…
    BioSpace · 4h agoNeutral↗ source
← prev
page 1 of 158
next →
116
fda medwatch112
globenewswire health73
fda press59
1820
Psychiatry & CNS1223
Ophthalmology1086
Endocrinology & Metabolism785
Pain784
Nephrology767
  • Biopharma firms showcase non-amyloid Alzheimer’s strategies at CTAD 2026 conference
    Biopharma companies including Biogen, Bristol Myers Squibb and Roche gathered in Boston for the Clinical Trials on Alzheimer’s Disease (CTAD) 2026 conference, where they presented new data on their…
    BioSpace · 5h agoPositive↗ source
  • Novartis and BMS pause autoimmune CAR-T trials after patient deaths and safety concerns
    Novartis, Bristol Myers Squibb and several other biotech firms have recently encountered setbacks while developing therapies for autoimmune diseases. Some programs have been completely discontinued…
    BioSpace · 5h agoNegative readoutNegative↗ source
  • Tandem Diabetes Care gets FDA clearance for tubeless insulin delivery system with up to 7-day wear
    Tandem Diabetes Care announced that the FDA has cleared its Tandem Mobi system as a tubeless automated insulin delivery device. The clearance allows the device to be worn for up to seven days witho…
    Fierce Biotech · 7h agoRegulatoryPositive↗ source
  • BridgeBio's Morgan Paull and Christine Zhang Named BioSpace 40 Under 40, Emphasize Patient-Centric Model
    BridgeBio has seen two of its young executives, Morgan Paull and Christine Zhang, named to BioSpace’s 2026 40 Under 40 list. Their inclusion highlights the company’s rapid growth and focus on rare-…
    BioSpace · 4h agoPositive↗ source
  • Apple and OpenEvidence Begin Study of Experimental AI Health Chat App
    Apple and OpenEvidence have launched a study centered on an experimental AI-powered health chat application. The pilot allows users to link personal health data to the chatbot, which then provides…
    STAT · 8h agoNeutral↗ source
  • CLINUVEL to cut up to 20% of staff and move headquarters to New York
    CLINUVEL announced a strategic reorganization aimed at focusing resources on the U.S. market. The company will reduce its global workforce by 10% to 20%, affecting up to 21 of its 104 employees.…
    BioSpace · 8h agoLayoffsNegative↗ source
  • The infrastructure decisions that will enable tomorrow’s biggest breakthroughs
    Faster drug discovery depends on more than the model. What drug developers need to know about AI.
    BioPharma Dive · 14m ago↗ source
  • Your AI pilots aren’t stalling because of the AI – they’re stalling because of your environment
    As clinical AI adoption accelerates, trust, traceability and readiness matter more than ever.
    BioPharma Dive · 14m ago↗ source
  • Completing the circle: the next evolution in sustainable pharmaceutical blister packaging
    Discover how innovative PET and PP lidding are advancing sustainable pharmaceutical blister packaging.
    BioPharma Dive · 14m ago↗ source
  • Big-name investors pour $100M into DNA therapeutics developer Seawolf
    The startup, which also just disclosed an up to $1.2 billion partnership with Sanofi, is backed by Versant, MPM BioImpact, Eli Lilly and Novartis’ venture arm.
    BioPharma Dive · 14m ago↗ source
  • Opinion: STAT+: Candles and long baths can’t fix burned-out physicians
    The language around self-care for doctors puts the onus on them to fix themselves. But the system is to blame, writes Frances Mei Hardin.
    STAT · 44m ago↗ source
  • BeOne, Hengrui top list of China’s most powerful drugmakers
    A new STAT-WireScreen index ranks China's most valuable publicly traded biotech companies. See which one topped the list.
    STAT · 44m ago↗ source
  • After difficult two years, medical school group’s leadership isn’t letting its guard down post midterms
    After a tumultuous two years entangled in many consequential health and science policy debates, AAMCs isn’t ready to let its guard down.
    STAT · 44m ago↗ source
  • Opinion: Medical school should start after students take the Step 1 exam
    “It’s time for a radical reimagining of medical education,” write Rachel Fabi and Amy Caruso Brown.
    STAT · 44m ago↗ source
  • STAT+: With Stephen Miller as chief of staff, Kennedy’s MAHA agenda is reinvigorated
    The appointment of Stephen Miller as White House chief of staff has health secretary RFK Jr. invigorated. A top deputy is telling people it's go time for MAHA.
    STAT · 44m ago↗ source
  • Chinese scientists fired after child dies in gene editing study: report
    Chinese authorities have fired two researchers over their roles in the death of a child in a gene editing study, according to reports in Chinese state media.
    Fierce Biotech · 6h ago↗ source
  • FDA denies Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer, halting US entry
    The U.S. Food and Drug Administration issued a complete response letter rejecting Summit Therapeutics' biologics license application for ivonescimab, a PD-1xVEGF bispecific antibody intended for EG…
    BioSpace · 20h agoCRLNegative↗ source
  • STAT+: FDA rejects lung cancer treatment ivonescimab from Summit Therapeutics
    The FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.
    STAT · 19h ago↗ source
  • PharmaLogic acquires Lantheus radiopharma CDMO and New Jersey plant to launch transatlantic manufacturing platform
    PharmaLogic announced it will purchase Lantheus' radiopharmaceutical contract development and manufacturing organization (CDMO) along with a production plant in Springfield, New Jersey. Lantheus h…
    BioSpace · 2d agoDealNeutral↗ source
  • FDA issues complete response letter, rejecting Summit Therapeutics' ivonescimab for EGFR-mutated lung cancer
    The U.S. Food and Drug Administration sent a complete response letter to Summit Therapeutics, declining to approve its bispecific antibody ivonescimab for patients with previously treated EGFR‑muta…
    Fierce Biotech · 2d agoRegulatoryNegative↗ source
  • Novo files US and EU approval for etavopivat, its $1B acquired sickle-cell therapy
    Novo submitted regulatory applications in the United States and Europe for etavopivat, a sickle cell disease therapy it bought from Forma Therapeutics in a $1 billion transaction. The company says…
    BioPharma Dive · 2d agoApprovalPositive↗ source
  • Takeda narcolepsy pill receives DEA clearance as Oura-Lilly deal raises conflict concerns and Pfizer exits Canadian Premarin market
    Takeda announced that its experimental narcolepsy medication has been cleared by the U.S. Drug Enforcement Administration, marking the first regulatory nod for a therapy aimed at treating excessive…
    STAT · 2d agoRegulatoryPositive↗ source
  • Neuroscience startups attract $450M in recent funding, Oyster Therapeutics secures $60M Series A
    Venture capital activity around neuroscience has picked up again, with five neurology-focused startups collectively raising about $450 million in the past few weeks. Data from BioPharma Dive show…
    BioPharma Dive · 2d agoDealPositive↗ source